Scientific advice for orphan drugs: Critical points and perspectives

Pharmaceuticals Policy and Law

Volumn 12, Issue 1-2, 2010, Pages 45-48

  Garcia, Jordi Llinares ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

Committee for Orphan Medicinal Products; Orphan designation; Protocol Assistance; significant benefit

Indexed keywords

ORPHAN DRUG;

AUTHORITY; CLINICAL PROTOCOL; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC ASPECT; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; HUMAN; ICELAND; LIECHTENSTEIN; NORWAY; PATIENT CARE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; RISK BENEFIT ANALYSIS; SCIENCE; SHORT SURVEY;

EID: 78049385254     PISSN: 13892827     EISSN: None     Source Type: Journal    
DOI: 10.3233/PPL-2010-0264     Document Type: Short Survey

References (1)

1. http://www.emea.europa.eu/htms/human/sciadvice/Scientific.htm.